CAMRF (Camurus AB) Defensive Interval Ratio


CAMRF Camurus AB CAMRF
81 GF Score
Price $61.01
GF Value $73.90
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Camurus AB Defensive Interval Ratio?

CAMRF
81GF Score
Camurus AB CAMRF
Defensive Interval Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Camurus AB (CAMRF) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of $61.01 is trading 17.4% below its estimated GF Value™ of $73.90. GuruFocus considers Camurus AB to be Modestly Undervalued.

Key valuation signals for CAMRF:

  • Defensive Interval Ratio:
  • GF Value™: $73.90 vs. price of $61.01 (17.4% below fair value)
  • GF Score™: 81/100 with 1 warning sign

No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
81GF Score

Get the complete analysis for CAMRF

Defensive Interval Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$61.01
Price
$73.90
GF Value